ANI Pharmaceuticals director granted 4,357 restricted shares

Leonard Matthew J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Leonard Matthew J reported acquisition or exercise transactions in this Form 4 filing.

ANI Pharmaceuticals director Matthew J. Leonard received a grant of 4,357 shares of common stock as a restricted stock award. The award was granted at no cash cost per share and is part of his equity-based compensation. These restricted shares will vest in full on May 21, 2027, meaning he must remain eligible through that date to receive them outright. After this grant, Leonard directly holds a total of 11,221 shares of ANI Pharmaceuticals common stock, indicating this is a relatively small, routine compensation-related award rather than a market purchase or sale.

Insider Trade Summary

Grant/Award: 4,357 shares

Grant/Award 1 txn

Insider Leonard Matthew J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,357	$0.00	$0.00

Holdings After Transaction: Common Stock — 11,221 shares (Direct)

Footnotes (1)

1. F1. Represents a restricted stock award that will vest in full on May 21, 2027.

Key Figures

Restricted stock award: 4,357 shares Grant price: $0.00 per share Holdings after grant: 11,221 shares +1 more

4 metrics

Restricted stock award 4,357 shares Grant of common stock on May 21, 2026

Grant price $0.00 per share Equity compensation grant, not a market purchase

Holdings after grant 11,221 shares Total direct common stock holdings following transaction

Vesting date May 21, 2027 Restricted stock award vests in full on this date

Key Terms

restricted stock award, vest in full, Form 4, non-derivative, +1 more

5 terms

restricted stock award financial

"Represents a restricted stock award that will vest in full on May 21, 2027."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

vest in full financial

"Represents a restricted stock award that will vest in full on May 21, 2027."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"transaction_type": "non-derivative""

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Matthew J. Leonard?

ANI Pharmaceuticals director Matthew J. Leonard received 4,357 shares of common stock as a restricted stock award. This was a compensation-related grant, not an open-market trade, and increased his direct holdings to 11,221 shares following the transaction.

Was the ANI Pharmaceuticals (ANIP) insider award to Matthew J. Leonard an open-market purchase?

No, the 4,357 shares reported for Matthew J. Leonard were granted as a restricted stock award at zero cash price. This represents equity compensation rather than an open-market buy or sell, so it carries different implications than a discretionary stock purchase.

When do Matthew J. Leonard’s restricted ANI Pharmaceuticals (ANIP) shares vest?

The 4,357 restricted shares granted to Matthew J. Leonard will vest in full on May 21, 2027. Vesting means the shares become fully owned at that date, typically contingent on continued service or meeting any applicable award conditions.

How many ANI Pharmaceuticals (ANIP) shares does Matthew J. Leonard hold after this Form 4 transaction?

Following the restricted stock grant, Matthew J. Leonard directly holds 11,221 shares of ANI Pharmaceuticals common stock. This total includes the newly awarded 4,357 restricted shares that are scheduled to vest on May 21, 2027, assuming vesting conditions are satisfied.

What does the Form 4 code “A” mean in the ANI Pharmaceuticals (ANIP) filing?

The Form 4 transaction code “A” indicates a grant, award, or other acquisition of securities. For ANI Pharmaceuticals, it shows Matthew J. Leonard received 4,357 restricted shares as equity compensation, rather than purchasing them on the open market for cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 09:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leonard Matthew J

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A(1)		4,357	A	$0	11,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in full on May 21, 2027.

Remarks:

	/s/ Matthew J. Leonard, by attorney-in-fact Meredith W. Cook	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)